Table 1.
Probability of CMV infection, mortality, and GVHD
| Variable | aHR | 95% CI | P |
|---|---|---|---|
| CMV (any viremia) | |||
| Vancomycin* | 1.225 | 0.626-2.397 | .55 |
| Cefepime* | 0.799 | 0.425-1.501 | .48 |
| Anaerobic antibiotics* | 1.427 | 0.929-2.192 | .10 |
| Mismatch/unrelated donor | 1.356 | 0.861-2.135 | .19 |
| CMV seronegative donor | 1.015 | 0.682-1.510 | .94 |
| GVHD 3-4 | 0.759 | 0.360-1.603 | .47 |
| Lymphoid malignancy | 1.276 | 0.836-1.946 | .26 |
| Clinically significant CMV infection | |||
| Vancomycin* | 0.961 | 0.422-2.193 | .93 |
| Cefepime* | 0.936 | 0.433-2.026 | .87 |
| Anaerobic antibiotics* | 1.937 | 1.176-3.193 | .01 |
| Mismatch/unrelated donor | 2.698 | 1.478-4.924 | .001 |
| CMV seronegative donor | 1.309 | 0.824-2.079 | .25 |
| GVHD 3-4 | 0.743 | 0.328-1.681 | .47 |
| Lymphoid malignancy | 2.184 | 1.339-3.560 | .002 |
| All-cause mortality | |||
| Vancomycin* | 0.94 | 0.32-2.78 | .91 |
| Cefepime* | 1.53 | 0.58-4.08 | .39 |
| Anaerobic antibiotics* | 3.11 | 1.60-6.04 | .0008 |
| Age | 1.02 | 0.99-1.05 | .06 |
| Mismatch/unrelated donor | 1.29 | 0.56-2.97 | .55 |
| Comorbidity score ≥2 | 0.84 | 0.33-2.15 | .71 |
| GVHD 3-4 | 1.92 | 0.81-4.56 | .14 |
| Acute leukemia† | 0.92 | 0.49-1.74 | .80 |
| cs-CMVi | 1.21 | 0.64-2.28 | .55 |
| Bacteremia as indication for antibiotics‡ | 0.83 | 0.33-2.08 | .69 |
| Nonrelapse mortality | |||
| Vancomycin* | 1.28 | 0.27-6.07 | .75 |
| Cefepime* | 2.65 | 0.68-10.4 | .16 |
| Anaerobic antibiotics* | 4.23 | 1.81-9.86 | .0008 |
| Age | 1.03 | 1.00-1.01 | .051 |
| Mismatch/unrelated donor | 1.26 | 0.42-3.78 | .68 |
| Comorbidity score | 0.41 | 0.15-1.10 | .08 |
| GVHD 3-4 | 1.79 | 0.66-4.87 | .26 |
| Acute leukemia† | 1.37 | 0.64-2.95 | .42 |
| cs-CMVi | 1.31 | 0.58-2.98 | .52 |
| Bacteremia as indication for antibiotics‡ | 0.93 | 0.33-2.62 | .89 |
| GVHD 3-4 | aOR | 95% CI | P |
| Vancomycin* | 8.91 | 0.73-109 | .09 |
| Cefepime* | 0.49 | 0.10-2.44 | .38 |
| Anaerobic antibiotics* | 5.46 | 1.24-24.0 | .02 |
| Mismatch/unrelated donor | 0.55 | 0.11-2.64 | .46 |
| Age | 0.99 | 0.95-1.04 | .83 |
| Graft source (PBSC) | 0.36 | 0.06-2.27 | .27 |
Cox proportional hazards regression model was used for CMV and mortality. Logistic regression analysis was used to examine the risk factors for development of GVHD.
aHR, adjusted hazard ratio; aOR, adjusted odds ratio; CI, confidence interval; PBCS, peripheral blood stem cell.
*
Compared with reference (ie, no corresponding antibiotic).
†
Includes acute myeloid leukemia, acute lymphoid leukemia, and acute leukemia of ambiguous lineage.
‡
Compared with reference (ie, antibiotics for prophylaxis, culture negative fever, and other).